← Leaderboards
Jelena Gvozdenovic Jeremic
Nostopharma, Llc
$770,982
Attributed
$770,982
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $407.8K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$770,982 · 2
By mechanism
R21$407,792 · 1
R43$363,190 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Therapeutic Effect”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Cynthia M Visness · Rho Federal Systems Division, Inc.$14,006,776
Research focus
Therapeutic EffectScreeningRare Genetic DisorderSoft TissueSide EffectDoseMesenchymal Stem CellsPathway InteractionsSeminalSmoothened Signaling PathwayToxic EffectArsenic TrioxideFormulationErinaceidaeHeterotopic OssificationInhibitorOsteoblastsOsteogenesisDrug RepurposingAuthorization DocumentationAreaAffectEncapsulatedFrequencies
Grant awards (3)
Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva$407,792
R21 · FY2025 · TR · contact PI
Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease$44,394
R43 · FY2024 · TR · contact PI
Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease$318,796
R43 · FY2023 · TR · contact PI